Literature DB >> 10953098

Antigen-processing machinery breakdown and tumor growth.

B Seliger1, M J Maeurer, S Ferrone.   

Abstract

Defects in the major histocompatibility complex (MHC) class I antigen-processing machinery (APM) have been described in tumors of different histology. Murine data suggest that defects in the MHC class II APM might also be associated with malignant transformation of human cells. This article describes the pathophysiology of the MHC class I and II APM, reviews APM abnormalities in tumor cells and discusses their role in the escape of tumor cells from in vitro recognition by T cells.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10953098     DOI： 10.1016/s0167-5699(00)01692-3

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  105 in total

Review 1.  Diversity in MHC class II antigen presentation.

Authors:  John H Robinson; Alexei A Delvig
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

2.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

3.  Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome.

Authors:  Qian Jiang; Hong-ya Pan; Dong-xia Ye; Ping Zhang; Lai-ping Zhong; Zhi-yuan Zhang
Journal:  Tumour Biol       Date:  2010-06-08

4.  Oncoantigens for an immune prevention of cancer.

Authors:  Elisabetta Bolli; Elena Quaglino; Maddalena Arigoni; Pier-Luigi Lollini; Raffaele Calogero; Guido Forni; Federica Cavallo
Journal:  Am J Cancer Res       Date:  2010-12-20       Impact factor: 6.166

5.  Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.

Authors:  Juergen Bukur; Felix Herrmann; Diana Handke; Christian Recktenwald; Barbara Seliger
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

6.  Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.

Authors:  Martin H Pedersen; Brian L Hood; Hans Christian Beck; Thomas P Conrads; Henrik J Ditzel; Rikke Leth-Larsen
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

7.  Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

Authors:  Ali R Jazirehi; James S Economou
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

8.  Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.

Authors:  Ahmad Al-Sukaini; Francis J Hornicek; Zachary S Peacock; Leonard B Kaban; Soldano Ferrone; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2017-07-19       Impact factor: 4.176

9.  Epigenetic control of the immune escape mechanisms in malignant carcinomas.

Authors:  A Francesca Setiadi; Muriel D David; Robyn P Seipp; Jennifer A Hartikainen; Rayshad Gopaul; Wilfred A Jefferies
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

10.  Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Authors:  Simone Kayser; Iris Watermann; Christine Rentzsch; Toni Weinschenk; Diethelm Wallwiener; Brigitte Gückel
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-26       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.